XML 176 R99.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Equity (Share-based Payments to Employees, Non-marketable Options) (Details) shares in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2023 shares
Non-marketable Options [Member] | Officers and senior employees [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Expiration date | August 20, 2025 |
Non-marketable Options [Member] | Officers and senior employees [Member] | June 30, 2016 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 3,035 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Expiration date | June 30, 2023 |
Non-marketable Options [Member] | Officers and senior employees [Member] | February 14, 2017 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Expiration date | February 14, 2024 |
Non-marketable Options [Member] | Officers and senior employees [Member] | June 20, 2017 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 6,868 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Expiration date | June 20, 2024 |
Non-marketable Options [Member] | Officers and senior employees [Member] | March 6 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 5,554 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Expiration date | March 6, 2025 |
Non-marketable Options [Member] | Officers and senior employees [Member] | May 14, 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Expiration date | May 14, 2025 |
Non-marketable Options [Member] | Officers and senior employees [Member] | February 14 2023 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Non-marketable Options [Member] | Former chairman of BOD [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Non-marketable Options [Member] | Former chairman of BOD [Member] | September 5, 2016 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 186 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Expiration date | June 30, 2023 |
Non-marketable Options [Member] | Former chairman of BOD [Member] | August 2, 2017 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 165 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Non-marketable Options [Member] | Former chairman of BOD [Member] | August 20, 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 403 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Non-marketable Options [Member] | Former chairman of BOD [Member] | February 14 2023 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Expiration date | 5 years after the grant date |
Non-marketable Options [Member] | Former Ceo [Member] | February 14, 2017 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 114 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Non-marketable Options [Member] | Former Ceo [Member] | May 14, 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 385 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Non-marketable Options [Member] | Former Ceo [Member] | June 27, 2019 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 3,512 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 2 equal tranches: (1) half at the end of 24 months after the grant date. (2) half at the end of 36 months after the grant date. |
Expiration date | 5 years after the grant date |
Non-marketable Options [Member] | Former Ceo [Member] | March 30, 2022 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 1,941 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Expiration date | 5 years after the grant date |
Non-marketable Options [Member] | Officers and senior manager [Member] | April 15, 2019 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 13,242 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 2 equal tranches: (1) half at the end of 24 months after the grant date. (2) half at the end of 36 months after the grant date. |
Expiration date | 5 years after the grant date |
Non-marketable Options [Member] | Chairman BOD [Member] | May 29 2019 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 2,169 | [1]
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 2 equal tranches: (1) half at the end of 24 months after the grant date. (2) half at the end of 36 months after the grant date. |
Expiration date | 5 years after the grant date |
Non-marketable Options [Member] | Chairman BOD [Member] | March 30, 2022 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 1,055 |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Expiration date | 5 years after the grant date |
Non-marketable Options [Member] | Senior Employees [Member] | June 30, 2021 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 647 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 2 equal tranches: (1) half at the end of 24 months after the grant date. (2) half at the end of 36 months after the grant date. |
Expiration date | 5 years after the grant date |
Non-marketable Options [Member] | Senior Employees [Member] | February 8, 2022 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 9,294 |
Issuance's details | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, as amended in June 2016 (hereinafter – the amended 2014 Equity Compensation Plan). |
Instrument terms | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Expiration date | 5 years after the grant date |
Non-marketable Options [Member] | Senior Managers [Member] | February 14 2023 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 461 |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Restricted shares [Member] | Officers and senior employees [Member] | March 6 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 1,726 |
Issuance's details | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting). |
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Restricted shares [Member] | Former chairman of BOD [Member] | August 20, 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 47 |
Issuance's details | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting). |
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Restricted shares [Member] | Icls Directors Excluding Icls Ceo And Chairman Of Bod [Member] | January 10, 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 137 |
Issuance's details | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting). |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
Restricted shares [Member] | Icl Directors Excluding Directors Who Are Officers Or Directors Of Il Corp Ltd Member | April 23, 2020 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 177 |
Issuance's details | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the Grant Date (the approval date of the annual General Meeting of shareholders). |
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Vesting conditions | 3 equal tranches: (1) one third on January 1, 2021 (2) one third on January 1, 2022 (3) one third on January 1,2023 |
Restricted shares [Member] | Former Ceo [Member] | May 14, 2018 [Member] |  |
Disclosure of terms and conditions of share-based payment arrangement [line items] |  |
Number Of Instruments | 121 |
Issuance's details | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the approval date of the General Meeting). |
Instrument terms | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. |
Vesting conditions | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date |
[1] | The options were issued upon Mr. Doppelt's entry into office on July 1, 2019.

X
- References No definition available. + Details
Name: | icl_NumberOfInstruments
Namespace Prefix: | icl_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of the maximum term of options granted for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2023-01-01 -Paragraph 45 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of the method of settlement (for example, whether in cash or equity) for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2023-01-01 -Paragraph 45 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2023-01-01 -Paragraph 45 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of a share-based payment arrangement that existed at any time during the reporting period. [Refer: Share-based payment arrangements [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2023-01-01 -Paragraph 45 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=icl_NonMarketableOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_OfficersAndSeniorEmployeesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_June302016Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_February142017Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_June202017Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_March62018Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_May142018Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_February142023Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_FormerChairmanBoardOfDirectorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_September52016Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_August22017Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_August202018Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_ChiefExecutiveOfficersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_June272019Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_March302022Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_OfficersAndSeniorManagerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_April152019Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_ChairmanBoardOfDirectorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_May292019Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_SeniorEmployeesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_June302021Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_February82022Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_SeniorManagersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=icl_RestrictedSharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_IclsDirectorsExcludingIclsCeoAndChairmanOfBodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_January102018Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_EmployeeFunctionAxis=icl_IclDirectorsExcludingDirectorsWhoAreOfficersOrDirectorsOfIlCorpLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | icl_GrantDateAxis=icl_April232020Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |